Wednesday, January 24, 2018 4:19:36 PM
Business Wire Business WireJanuary 24, 2018
LATHAM, N.Y.--(BUSINESS WIRE)--
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted the Expedited Access Pathway (EAP) designation to the Company’s NanoKnife® System and proposed indication for use for the treatment of Stage III pancreatic cancer.
The EAP program is designed to help patients gain more timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, for which no approved or cleared alternatives exist. This is achieved by expediting the device’s assessment and review processes through more interactive and timely communication with the FDA, pre- and post-market balance of data collection requirements, efficient and flexible clinical study design, FDA review team support and Agency senior management engagement, and priority review.
Pursuant to the recently enacted 21st Century Cures Act, the FDA has released draft guidance for a Breakthrough Devices Program, which, when finalized, will supersede the EAP. The FDA has indicated that all devices that receive EAP designation will gain Breakthrough Device designation when the guidance document becomes final.
Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc., commented, “The Expedited Access Pathway and Breakthrough Devices Program is an important and meaningful initiative to prioritize review and approval for novel, innovative devices needed by patients for the treatment of life-threatening diseases and conditions. We are thrilled that the FDA has granted the EAP designation to NanoKnife for the treatment of Stage III pancreatic cancer and are excited to continue working with the FDA toward approval of NanoKnife as a treatment for the underserved patient population suffering from this deadly disease.”
Recent ANGO News
- AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions • Business Wire • 05/06/2024 08:45:00 PM
- US Index Futures Rise, Oil Dips Slightly • IH Market News • 04/04/2024 11:31:45 AM
- AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture • Business Wire • 04/04/2024 11:00:00 AM
- AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE • Business Wire • 04/04/2024 10:45:00 AM
- AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc. • Business Wire • 04/01/2024 09:26:00 PM
- AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024 • Business Wire • 03/19/2024 08:01:00 PM
- AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference • Business Wire • 03/06/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:49:30 AM
- AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million • Business Wire • 02/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:14:00 PM
- AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease • Business Wire • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 12:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 12:30:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/08/2024 09:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 12:15:29 PM
- AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance • Business Wire • 01/05/2024 12:00:00 PM
- AngioDynamics to Present at the J.P. Morgan Healthcare Conference • Business Wire • 12/21/2023 09:01:00 PM
- AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024 • Business Wire • 12/07/2023 09:01:00 PM
- AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism • Business Wire • 12/07/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2023 01:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/05/2023 09:15:12 PM
- Wednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and more • IH Market News • 10/04/2023 11:22:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 11:15:31 AM
- AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance • Business Wire • 10/04/2023 11:00:00 AM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM